Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07123857

Impact of Point-of-care Lactate Testing as Triage Supplement on Patient Management Using Manchester Triage System

Although the Manchester Triage System (MTS) is widely used and validated internationally, it has some limitations. Its accuracy is moderate, especially for children and the elderly. Rising patient numbers and overcrowded emergency departments increase wait times, sometimes beyond safe limits. In Slovenia, MTS has been in use for 14 years without major updates, despite a significant rise in emergency visits. The yellow triage category (60-minute wait time) includes a very diverse group of patients, some of whom might require faster care. Older patients, in particular, often show atypical symptoms and may be under-triaged. Including rapid bedside lab tests, like blood lactate levels, could improve risk assessment and triage accuracy. Elevated lactate is linked with higher mortality and can help identify critically ill patients more effectively. The proposed study is a prospective, randomized trial involving two groups of patients in the yellow triage category, all of whom will have their capillary blood lactate levels measured. Patients with normal lactate levels will be excluded. Only patients with elevated lactate will be compared. The test group will be re-triaged to the orange category and treated more urgently. The control group, despite also having high lactate levels, will remain in the yellow category, and their elevated lactate values will not be shared with the treating physician. Randomization will be based on the patient's birth date (even days = test group, odd days = control group). Only the nurse will know the result, maintaining physician blinding to avoid the Hawthorne effect-changes in behavior due to awareness of being studied. Standard lab tests will be performed later during treatment as deemed necessary by the attending doctor.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Medical Center Maribor

Maribor, Slovenia

Location status: Recruiting

Location contact

Jerica Zaloznik Djordjevic, MD

CONTACT

[email protected]

00386 31 696 858

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • signed consent, yellow MTS triage category

Exclusion criteria

  • pregnant women, trauma patients, epileptic seizures, adrenergic therapy in prehospital unit

Treatment and study plan

re-triage

Diagnostic Test

Patients in the test group will be re-triaged into the orange MTS category.

Primary outcomes

  1. Vasoactive drug use

    Time frame: 30-day

Secondary outcomes

  1. In-hospital mortality

    Time frame: 30-day

  2. ICU admission

    Time frame: 30-day

Study contacts

Contact information is provided by the study sponsor or research team.

Jerica Zaloznik Djordjevic, MD

CONTACT

[email protected]

00386 31 696 858

Sponsors and collaborators

Lead sponsor

University Medical Centre Maribor

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 14, 2025
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.